Analystreport

Vistagen Therapeutics Inc (NASDAQ: VTGN) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $6.00 price target on the stock.

VistaGen Therapeutics, Inc.  (VTGN) 
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vistagen.com